

With the patronage of



**SIE - Società Italiana di Ematologia**

# Current Challenges in Hematology 3rd edition

**Rome, NH Vittorio Veneto**

**22 - 23 January 2025**

**PRESIDENT**

**Alessandro Isidori**

**HONORARY PRESIDENTS**

**Giuseppe Visani**

**Adolfo de la Fuente Burguera**

**SCIENTIFIC COMMITTEE**

**Alessandro Isidori**

**Antonio Cuneo**

**Adolfo de la Fuente Burguera**

**Francesco Passamonti**

**Alexander Perl**

**Umberto Vitolo**

**Eunice Wang**

**Elena Zamagni**

# FACULTY

**ADES LIONEL**  
Paris

**BRECCIA MASSIMO**  
Rome

**CANDONI ANNA**  
Modena

**CONCONI ANNARITA**  
Biella

**CUNEO ANTONIO**  
Ferrara

**DAVER NAVAL**  
Houston (USA)

**DE LA FUENTE BURGUERA ADOLFO**  
Madrid

**DI ROCCO ALICE**  
Rome

**DÖHNER KONSTANZE**  
Ulm

**FATTIZZO BRUNO**  
Milan

**FERRARA FELICETTO**  
Naples

**FERRERI ANDRÉS J. M.**  
Milan

**GAIDANO GIANLUCA**  
Novara

**GENTILE MASSIMO**  
Cosenza

**ISIDORI ALESSANDRO**  
Pesaro

**INNOCENTI IDANNA**  
Rome

**JABBOUR ELIAS**  
Houston (USA)

**JONAS BRIAN ANDREW**  
Sacramento

**LADETTO MARCO**  
Alessandria

**LAURENTI LUCA**  
Rome

**LUCIGNANO MARIANO**  
Salerno

**MARTELLI MAURIZIO**  
Rome

**MARTINO MASSIMO**  
Reggio Calabria

**MATEOS MARIA VICTORIA**  
Salamanca (Spain)

**MAURO FRANCESCA ROMANA**  
Rome

**MINA ROBERTO**  
Turin

**MONTORO JULIA**  
Barcelona (Spain)

**MUNIR THALA**  
Leeds (UK)

**MURRU ROBERTA**  
Cagliari

**MUSTO PELLEGRINO**  
Bari

**MUSURACA GERARDO**  
Meldola (FC)

**PAGANO LIVIO**  
Rome

**PALANDRI FRANCESCA**  
Bologne

**PAPAYANNIDIS CRISTINA**  
Bologne

**PASSAMONTI FRANCESCO**  
Milan

**PERL ALEXANDER**  
Philadelphia (USA)

**POLONI ANTONELLA**  
Ancona

**RIGACCI LUIGI**  
Rome

**RIVAS MARTA**  
Buenos Aires (Argentina)

**ROSSI ELENA**  
Rome

**SANNA ALESSANDRO**  
Florence

**SICA SIMONA**  
Rome

**SPORTOLETTI PAOLO**  
Perugia

**VENDITTI ADRIANO**  
Rome

**VISANI GIUSEPPE**  
Pesaro

**VISENTIN ANDREA**  
Padua

**VITOLO UMBERTO**  
Candiolo, Turin

**VOSO MARIA TERESA**  
Rome

**WANG EUNICE**  
Buffalo (USA)

**ZAMAGNI ELENA**  
Bologne

# 22 January 2025

08.50 Congress open  
Alessandro Isidori

## 09.00 SESSION I Current challenges in Lymphomas

Chairmen: Maurizio Martelli, Umberto Vitolo

09.00 Perspectives in mantle cell lymphoma  
Marco Ladetto

09.20 Perspectives in marginal zone lymphoma  
Annarita Conconi

09.40 CAR-T in DLBCL  
Alice Di Rocco

10.00 Therapeutic options in patients with relapsed/refractory DLBCL not eligible to CAR-T  
Gerardo Musuraca

10.20 Current challenges in advanced-stage Hodgkin disease  
Luigi Rigacci

10.40 Talk-show: Bispecific antibodies for relapsed/refractory B cell lymphomas: a new gold standard?  
Maurizio Martelli, Umberto Vitolo, Marco Ladetto, Gerardo Musuraca

11.10 Coffee break

## 11.30 SESSION II Multiple Myeloma

Chairmen: Maria Victoria Mateos, Elena Zamagni

11.30 How I diagnose and treat high risk MM  
Roberto Mina

11.50 Bispecific antibodies: how to choose them and how to manage them  
Maria Victoria Mateos

12.10 CAR-T: patient's selection and management  
Elena Zamagni

12.30 Bridging the gap: how to integrate therapeutic options for intermediate-fit patients at relapse  
Pellegrino Musto

12.50 Talk-show: Bispecific antibodies for multiple myeloma: alternative or complementary to CAR-T? How to sequence them?  
Maria Victoria Mateos, Elena Zamagni, Roberto Mina

## 13.30-14.15 Lunch Symposium (NO ECM)

With the contribution of BEIGENE  
Puccini Room

**"SETTING NEW STANDARD IN CLL: ZANUBRUTINIB AS A BALANCE BETWEEN EFFICACY AND SAFETY"**  
Chairmen: Luca Laurenti, Francesca Romana Mauro

13.30 Welcome and introduction  
Luca Laurenti

13.45 Clinical experiences with Zanubrutinib in CLL:  
- First line treatment  
Idanna Innocenti  
- Treatment of R/R patients  
Mariano Lucignano

14:00 Conclusions and take-home messages  
Francesca Romana Mauro

## 14.15-15.00 Symposium (NO ECM)

With the contribution of ASTRAZENECA  
Puccini Room

**"THE TREATMENT CHOICE IN 1L CHRONIC LYMPHOCYTIC LEUKEMIA: "ONE SIZE FITS ALL"?"**  
Chair: Alessandro Isidori

14.15 The efficacy and safety of Acalabrutinib: from clinical trials to RWE  
Alessandro Sanna

14.30 The right treatment for the right patient: Biology vs Age & Fitness  
Roberta Murru

14.45 Panel discussion  
Roberta Murru, Alessandro Sanna

## 15.00-15.45 Symposium (NO ECM)

With the contribution of JANSSEN CILAG  
Puccini Room

**INNOVATION IN HEMATOLOGY: PROMISING THERAPIES IN MULTIPLE MYELOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA**  
Chair: Alessandro Isidori

15.00 From Frontline to Relapse: The Journey through MM  
Elena Zamagni

15.20 From Frontline to Relapse: The Journey through CLL  
Paolo Sportoletti

## 15.45-16.15 Symposium (NO ECM)

With the contribution of ABBVIE  
Puccini Room

**HOW TO OVERCOME THE CURRENT CHALLENGES IN DLCL AND CLL**

15.45 DLBCL  
Chair: Andrés J. M. Ferreri  
Epcoritamab deep and durable responses: 3-year update  
Alice Di Rocco  
15.55 Discussione e Q&A

16.00 CLL  
Chair: Massimo Gentile  
V+X: venetoclax as the backbone therapy in CLL  
Andrea Visentini  
16.10 Discussione e Q&A

**16.15 - 16.30**

### **Sponsored Lecture (NO ECM)**

With the contribution of ELI LILLY  
Puccini Room

**16.15** Pirtobrutinib and the new treatment algorithm for relapsed or refractory (R/R) mantle cell lymphoma  
Gerardo Musuraca

**16.30** Open coffee break

**16.40 - 17.10**

Talk show: Is all good enough in PNH?  
Bruno Fattizzo, Simona Sica

### **17.10 SESSION III**

### **Chronic lymphocytic leukemia**

Chairmen: Francesca Romana Mauro, Antonio Cuneo

**17.10** How biology influences treatment in CLL  
Gianluca Gaidano

**17.30** CLL therapy guided by measurable residual disease  
Tahla Munir

**17.50** Perspectives in refractory/resistant CLL  
Paolo Sportoletti

**18.10** Talk-Show: Fixed duration versus continuous therapy in 1L CLL: the final frontier  
Antonio Cuneo, Gianluca Gaidano, Francesca Romana Mauro, Tahla Munir, Paolo Sportoletti

**18.40 SESSION IV**

### **Myeloproliferative neoplasms**

Chairmen: Francesco Passamonti, Massimo Breccia

**18.40** How I treat polycythemia vera  
Francesco Passamonti

**19.00** Rusfertide in polycythemia vera: data from clinical trials  
Alessandro Isidori

**19.15** New treatment options for CML patients in second or subsequent lines of therapy  
Massimo Breccia

**19.35** Current management of patients with myelofibrosis  
Francesca Palandri

**19.55** Discussion

**20.30** Day-1 closing

# 23 January 2025

09.00 Lecture: Challenges in treatment of immune thrombocytopenia (ITP)

Elena Rossi

## 09.20 SESSION V

### Myelodysplastic syndromes

Chairmen: Maria Teresa Voso, Antonella Poloni

09.20 Germline predisposition: clinical and ethical relevance

Julia Montoro

09.40 Perspectives and innovations in low-risk MDS

Lionel Aedes

10.00 Perspectives and innovations in high-risk MDS

Eunice Wang

10.20 Discussion

## 10.30 SESSION VI

### Acute Myeloid Leukemia (I)

Chairmen: Konstanze Döhner, Giuseppe Visani

10.30 How molecular information guide treatment decision-making in AML patients

Konstanze Döhner

10.50 Treatment of high-risk AML

Eunice Wang

11.10 Optimal approaches to frontline FLT3 ITD AML

Alexander Perl

11.30 Discussion

11.40 Coffee break

## 12.00 SESSION VII

### Acute Myeloid Leukemia (II)

Chairmen: Alessandro Isidori, Alexander Perl

12.00 Optimizing outcomes and practical management of patients treated with HMA+venetoclax based regimen

Brian Andrew Jonas

12.20 Menin inhibitors in AML

Eunice Wang

12.40 Acute promyelocytic leukemia in 2025

Maria Teresa Voso

13.00 Discussion

## 13.20-14.20

### Lunch Symposium (NO ECM)

With the contribution of DAIICHI SANKYO  
Puccini Room

FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 Inhibitors

Chair: Adriano Venditti

13.20 Welcome and introduction

Adriano Venditti

13:25 Is FLT3-ITD mutated AML really an intermediate-risk disease?

Maria Teresa Voso

13:40 Maintenance therapy in AML-FLT3-ITD + pts: what is the future?

Felicetto Ferrara

13:55 Talk-Show: how optimize treatment with FLT3i: is it time to define a sequencing strategy?

Introduction by Alessandro Isidori

## 14.20

### Sponsored Lecture (NO ECM)

With the contribution of ABBVIE  
Puccini Room

14.20 AML

Chair: Anna Candoni

Improving AML patients life with VEN+AZA

Alessandro Isidori

14.35 Discussione e Q&A

## 14.40

Talk-Show: Conditioning regimens and early complications in allogeneic stem cell transplantation

Massimo Martino, Alessandro Isidori

## 15.10 SESSION VII

### Breaking news from MD Anderson

Chairmen: Adolfo de la Fuente, Alessandro Isidori

15.10 Breaking news in ALL

Elias Jabbour

15:30 Breaking news in AML

Naval Daver

15:50 Discussion

16.00 Lecture - Current treatment of adult patients with acute lymphoblastic leukemia

Cristina Papayannidis

## **16.20 SESSION VIII**

### **Acute Myeloid Leukemia (III)**

Chairmen: Felicetto Ferrara, Marta Rivas

**16.20 Maintenance in AML: a true alternative to allo-SCT for some patients?**

Adolfo de la Fuente Burguera

**16.40 Treatment of elderly patients with IDH1 +ve AML**

Adriano Venditti

**17.00 Alternative treatments for unfit patients with AML**

Alessandro Isidori

**17.20 Diagnosis and treatment of BPDCN**

Livio Pagano

**17.40 Discussion**

**17.50 Closing remarks – see you in 2026**

Alessandro Isidori

## CME INFO & REGISTRATION

Event n. 2007-434837

Objective n. 3

**15 CME Credits for: Hematologists and Biologists**

Free registration: [www.proeventi.it](http://www.proeventi.it)

pin : current2025 (DEEP ECM APP)

## ITALIAN ECM ACCREDITATION

Each participant, to obtain ECM credits, must attend at least 90% of the scientific work and complete the online ECM questionnaire with at least 75% of correct answers.

Attendance will be registered via QR code reader.

## VENUE

NH VITTORIO VENETO, Rome

[Corso d'Italia, 1, 00198 Roma RM](#)

CONFERENCE CENTER -1 FLOOR

ECM AREA: TIZIANO + BOTTICELLI

LUNCH ROOM: MASCAGNI

EXPO AREA: VERDI

SYMPOSIA ROOM: PUCCINI

## LANGUAGE

Italian speakers will present their works in Italian.

Foreign speakers will present their works in English.

Foreigners guests will receive the headset with simultaneous translation.

## EDUCATIONAL GRANT

The organization offers travel grants for those interested in participating.

You can send your application to [info@proeventi.it](mailto:info@proeventi.it)

The scientific committee will select the first 50 relevant applications.

## SCIENTIFIC SECRETARIAT

Alessandro Isidori

Federica Loscocco

## ORGANIZING SECRETARIAT



[www.proeventi.it](http://www.proeventi.it)

[info@proeventi.it](mailto:info@proeventi.it)

With the unrestricted educational grant of



PLATINUM SPONSOR

abbvie

GOLD SPONSOR

AstraZeneca 

 BeiGene

  
Daiichi-Sankyo

Johnson & Johnson


*Lilly*

SILVER SPONSOR

AMGEN

 Incyte

 Jazz Pharmaceuticals

 Otsuka  
Otsuka Pharmaceutical Italy S.r.l.

sanofi

SERVIER\*  
*moved by you*

BRONZE SPONSOR

 Bristol Myers Squibb

medac  
PHARMA

 KURA  
ONCOLOGY

 MENARINI  
group

 NOVARTIS

 sobi  
rare strength

 Takeda

CONTRIBUTORS

ALEXION<sup>®</sup>  
AstraZeneca Rare Disease

 GILEAD

 Protagonist  
Therapeutics

 Roche